The evolution of mendelian randomization for investigating drug effects

Gill, Dipender; Burgess, Stephen

View / Open Files

Bibliographic metadata (XML, 22Kb)

Published version (PDF, 285Kb)

Authors

Gill, Dipender

Burgess, Stephen

Publication Date

2022-02-03

Journal Title

PLOS Medicine

ISSN

1549-1277

Publisher

Public Library of Science

Volume

Issue

Language

Type

Other

This Version

VoR

Metadata

Show full item record

Citation

Gill, D., & Burgess, S. (2022). The evolution of mendelian randomization for investigating drug effects. [Other]. https://doi.org/10.1371/journal.pmed.1003898

Abstract

Dipender Gill and Stephen Burgess discuss the accompanying study by James Yarmolinsky and colleagues investigating the associations between genetically-proxied inhibition of antihypertensive drug targets and risk of common cancer subtypes using Mendelian randomization.

Keywords

Perspective, Biology and life sciences, Medicine and health sciences

Identifiers

pmedicine-d-21-05010

External DOI: https://doi.org/10.1371/journal.pmed.1003898

This record's DOI: https://doi.org/10.17863/CAM.81024

Rights

Licence:

http://creativecommons.org/licenses/by/4.0/

Statistics

Total file downloads (since January 2020). For more information on metrics see the IRUS guide.